The inhibitory activity of Lignosulfonic acid sodium on HIV-1 infection
Currently there are 25 drugs approved on the market for people who live with HIV-1. These drugs target various stages of the viral life cycle, mainly viral entry, fusion and reverse transcription1. As with all drugs, all of them have side-effects and are subject to drug-resistant mutations. Therefore, consistent efforts are needed for the search of new drug targets. In this report, using an in vitro pseudovirus assay, we were able to analyze the anti-HIV-1 activity of Lignosulfonic acid sodium. Lignosulfonic acid sodium salt (LSA) is usually used as industry material, but we found that it exhibited anti-HIV-1 activity. LSA exhibited potent HIV-1 inhibitory activities in a dose-dependent manner. In addition, we investigated the cytotoxcity of LSA using MTT colarimetric assay and determined the 50％ toxic dose (CC50) to be at 132μg/mL. When the concentration of LSA is 9μg/mL, which is much lower than CC50, the inhibition ratio of pseudotyped HIV-1 virus still more than 90％. In this study, we also showed that pseudotyped virus could be rapidly generated and used in a number of established cell lines with low background2, and adapted for evaluating anti-viral agents that act on the viral entry portal.
LSA pseudotyped virus inhibition
Hongyong Song Ying Chu Qin Wang Zhiwei Wu
Center for Public Health Research, Medical School, Nanjing University, Nanjing, 210093, China
国际会议
南京
英文
88-91
2010-05-12（万方平台首次上网日期，不代表论文的发表时间）